First half 1995 brings E for M back into profits
This article was originally published in Clinica
In the first half of this year, US cardiology company E for M turned in an operational profit of $2.3 million after two years in the red. E for M's business is straddling two continents since it bought 100-year-old Hellige (Germany) in autumn 1994. E for M has consolidated the businesses and improved cost control.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.